T.Man Pharmaceutical PCL (BKK: TMAN)
Thailand
· Delayed Price · Currency is THB 14.00
+0.10 (0.72%)
Dec 20, 2024, 10:00 AM ICT
T.Man Pharmaceutical PCL Cash Flow Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | 433.28 | 431.09 | 472.52 | 56.39 | 59.89 |
| Depreciation & Amortization | 101.99 | 97.87 | 75.09 | 70.36 | 70.69 |
| Loss (Gain) From Sale of Assets | -0.96 | -0.57 | 3.52 | 0.17 | -0.71 |
| Provision & Write-off of Bad Debts | -3.73 | -44.63 | 40.57 | 11.64 | 5.88 |
| Other Operating Activities | 12.32 | -66.84 | 101.77 | 16.04 | 17.06 |
| Change in Accounts Receivable | -44.47 | -42.97 | -289.24 | -76.82 | 92.52 |
| Change in Inventory | -17.49 | -125.25 | -62.83 | 101.77 | 7.75 |
| Change in Accounts Payable | 47.36 | 3.49 | 65.99 | 101.17 | -27.35 |
| Change in Other Net Operating Assets | 2.4 | 29.9 | 116.13 | -5 | -31.66 |
| Operating Cash Flow | 514.03 | 282.09 | 523.53 | 275.74 | 194.06 |
| Operating Cash Flow Growth | 32.99% | -46.12% | 89.86% | 42.09% | - |
| Capital Expenditures | -200.94 | -219.95 | -234.52 | -79.25 | -65.24 |
| Sale of Property, Plant & Equipment | -0.2 | - | - | 1.21 | 1.45 |
| Investment in Securities | - | - | - | 5 | - |
| Other Investing Activities | 1.83 | 1.24 | 20.08 | 0.05 | 0.43 |
| Investing Cash Flow | -196.99 | -216.38 | -177.36 | -72.99 | -63.35 |
| Short-Term Debt Issued | - | 28.81 | - | 19.61 | - |
| Long-Term Debt Issued | - | - | 50 | - | - |
| Total Debt Issued | 94.52 | 28.81 | 50 | 19.61 | - |
| Short-Term Debt Repaid | - | -60.38 | -79.57 | -210.2 | -60.8 |
| Long-Term Debt Repaid | - | -32.82 | -22.8 | -50.84 | -11.48 |
| Total Debt Repaid | -382.95 | -93.2 | -102.37 | -261.04 | -72.29 |
| Net Debt Issued (Repaid) | -288.43 | -64.4 | -52.37 | -241.43 | -72.29 |
| Issuance of Common Stock | - | 59.13 | - | - | - |
| Common Dividends Paid | -191.03 | -11.83 | - | - | - |
| Other Financing Activities | -28.08 | -7.75 | -8.82 | -6.03 | -7.56 |
| Financing Cash Flow | -507.55 | -24.85 | -61.19 | -247.46 | -79.85 |
| Net Cash Flow | -190.5 | 40.86 | 284.98 | -44.71 | 50.86 |
| Free Cash Flow | 313.1 | 62.15 | 289.02 | 196.49 | 128.83 |
| Free Cash Flow Growth | 222.07% | -78.50% | 47.09% | 52.52% | - |
| Free Cash Flow Margin | 14.25% | 3.14% | 14.27% | 15.55% | 14.30% |
| Free Cash Flow Per Share | 0.99 | 0.23 | 1.16 | 2.72 | 1.93 |
| Cash Interest Paid | 28.08 | 7.75 | 8.62 | 6.03 | 8.56 |
| Cash Income Tax Paid | 77.51 | 164.55 | 50.32 | 14.53 | 7.35 |
| Levered Free Cash Flow | 1,361 | -46.49 | 159.27 | 193.69 | - |
| Unlevered Free Cash Flow | 1,369 | -37.2 | 169.88 | 198.18 | - |
| Change in Net Working Capital | -1,143 | 243.28 | 50.82 | -156.44 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.